What is Revance Therapeutics, Inc. (RVNC) stock price today?

Revance Therapeutics, Inc. (RVNC) is currently trading at $3.65, up 0% today.

What is RVNC P/E ratio?

Revance Therapeutics, Inc.'s P/E ratio is -0.95. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is RVNC return on equity (ROE)?

Revance Therapeutics, Inc.'s return on equity (ROE) is 466.15%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Revance Therapeutics, Inc.'s market cap?

Revance Therapeutics, Inc. has a market capitalization of $381.02M.

NASDAQ · Biotechnology

Revance Therapeutics, Inc. (RVNC) Stock

$3.65 +0.00% NASDAQ: RVNC Healthcare

Valuation

Metric	Value
Price	$3.65
Market Cap	$381.02M
P/E Ratio	-0.95
P/B Ratio	-2.04
P/S Ratio	1.63
EPS (TTM)	$-3.83
52-Week High	$7.56
52-Week Low	$2.30
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	466.15%
ROA	-67.72%
ROCE	-81.39%
Gross Margin	34.98%
Operating Margin	-135.35%
Net Margin	-138.43%
Debt/Equity	-3.16
Current Ratio	3.80

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$0	$15.0M	$78.0M	$133.0M	$234.0M
Operating Profit	$-164.0M	$-273.0M	$-275.0M	$-272.0M	$-317.0M
Net Profit	$-156.0M	$-282.0M	$-287.0M	$-356.0M	$-324.0M
EPS	$-3.59	$-4.86	$-4.25	$-4.90	$-3.83
Op Margin	-39820.6%	-1782.5%	-353.1%	-205.3%	-135.3%

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$340.0M	$720.0M	$531.0M	$582.0M	$478.0M
Total Liabilities	$115.0M	$346.0M	$463.0M	$569.0M	$630.0M
Cash	$171.0M	$334.0M	$111.0M	$109.0M	$137.0M
Borrowings	$29.0M	$212.0M	$325.0M	$418.0M	$478.0M

Latest News

Prologis to Buy U.K.’s Segro for $18.8 Billion The Wall Street Journal · Aug 4, 2026 1 Mid-Cap Stock to Target This Week and 2 We Find Risky StockStory · Aug 4, 2026 LEG Immobilien reports steady rental growth amid FFO pressure Investing.com · Aug 4, 2026 Heat kills 16 in South Korea this summer: interior ministry AFP · Aug 4, 2026 Oil ticks up after selloff as talks to end US-Iran war remain uncertain Reuters · Aug 4, 2026

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-106.0M	$-179.0M	$-222.0M	$-194.0M	$-217.0M
Investing Cash Flow	$-35.0M	$25.0M	$-48.0M	$-162.0M	$103.0M
Financing Cash Flow	$-1.0M	$-40.0M	$8.0M	$-3.0M	$6.0M
Net Cash Flow	$98.0M	$165.0M	$-221.0M	$-1.0M	$30.0M
Free Cash Flow	$-109.0M	$-183.0M	$-240.0M	$-217.0M	$-223.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-2.48
FCF Yield	-58.65%
Quick Ratio	3.29
Interest Coverage	-16.37
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BCYPBig Cypress Acquisition Corp.	$8.44	-19.23%	19.63	$425.36M	0.00%
CKPTCheckpoint Therapeutics, Inc.	$4.26	+0.00%	-3.00	$367.72M	0.00%
CLYMClimb Bio, Inc.	$10.29	-0.19%	-13.18	$591.02M	0.00%
CTEVClaritev Corporation	$23.94	+0.93%	-1.41	$405.72M	0.00%
GTHXG1 Therapeutics, Inc.	$7.16	+0.14%	-7.70	$377.75M	0.00%

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company specializing in the research, manufacturing, and marketing of neuromodulators for diverse aesthetic and therapeutic uses across both domestic and international markets. The company's leading product candidate, DaxibotulinumtoxinA for injection, has concluded Phase III clinical evaluations for treating glabellar (frown) lines and cervical dystonia. This same drug is currently in Phase II clinical trials for addressing upper facial lines, moderate to severe dynamic forehead lines, and moderate to severe lateral canthal lines, following the successful completion of its Phase II trials for adult upper limb spasticity and plantar fasciitis. Beyond this, Revance is conducting preclinical studies for DaxibotulinumtoxinA as a potential migraine treatment and is developing a topical version for various indications. The company is also developing OnabotulinumtoxinA, intended as a biosimilar to BOTOX. A collaborative and licensing partnership with Viatris Inc. facilitates the development, manufacturing, and commercialization of onabotulinumtoxinA. Initially established in 1999 as Essentia Biosystems, Inc., the company officially rebranded as Revance Therapeutics, Inc. in April 2005 and maintains its corporate headquarters in Nashville, Tennessee.

Revance Therapeutics, Inc. is headquartered in US.

Revance Therapeutics, Inc. (RVNC) stock trades at $3.65 with a market capitalization of $381.02M. The stock is valued at a price-to-earnings (P/E) ratio of -0.95, price-to-book of -2.04, price-to-sales of 1.63. Over the past 52 weeks the stock has ranged between $2.30 and $7.56, and currently trades 51.7% below its 52-week high.

On profitability, Revance Therapeutics, Inc. generates a return on equity (ROE) of 466.15% — well above the market average, a sign of a high-quality business, return on capital employed of -81.39%, an operating margin of -135.35%, a net profit margin of -138.43%.

Official website: www.revance.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1211.40 +3.85% JNJ Johnson & Johnson $253.91 +2.13% ABBV AbbVie Inc. $283.52 +3.34% MRK Merck & Company, Inc. Common Stock (new) $147.37 +3.79% UNH UnitedHealth Group Incorporated Common Stock (DE) $395.62 +4.73% NVS Novartis AG $146.88 +3.14% AZN AstraZeneca PLC $162.03 +3.99% TMO Thermo Fisher Scientific Inc $673.20 +1.53% AMGN Amgen Inc. $426.11 +3.21% GILD Gilead Sciences, Inc. $153.54 +3.80% ABT Abbott Laboratories $102.97 +0.35% NVO Novo Nordisk A/S $38.12 +0.16%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides